SANA BIOTECHNOLOGY INC (SANA)
Health Care · Cell therapy and engineered cell therapeutics · NASDAQ
Sana Biotechnology is developing ex vivo and in vivo engineered cell therapy platforms to transform the treatment of diseases like type 1 diabetes, oncology, and autoimmune conditions.
What SANA BIOTECHNOLOGY INC does
Sana Biotechnology is a clinical-stage cell engineering company developing transformative therapeutics through ex vivo and in vivo cell engineering platforms. The company's lead program, SC451, is a hypoimmune platform (HIP)-engineered stem cell-derived pancreatic islet cell therapy for type 1 diabetes designed to achieve normal blood glucose without insulin injections or immunosuppression. Its second major program, SG293, is an in vivo CAR T cell therapy using a fusogen platform to deliver genetic payloads directly to T cells, targeting B cell malignancies and B cell-mediated autoimmune diseases.
Themes: Cell therapy / engineered cells, Type 1 diabetes / metabolic disease, CAR T cell therapy, In vivo gene delivery, Immunotherapy / oncology, Autoimmune disease, Regenerative medicine
Fundamentals
- Price$3.91 as of 2026-08-21 close
- Market cap$1.2B as of 2026-08-21
- 1-year return+8.6% 2025-08-21 close $3.60 → 2026-08-21 close $3.91
- P/En/a earnings data not available
- ROE-161.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta2.18 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How SANA compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SANA BIOTECHNOLOGY INC looks technically
SANA BIOTECHNOLOGY INC (SANA) is trading 4.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 98 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 40.3% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 4.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +4.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.44 | $3.44 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.76 | $3.76 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 3.03. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 98 trading days ago — a "death cross", a bearish long-term signal | 98 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 4.1% above | +4.1% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 19.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($3.24 to $4.12) — its "stochastic" reading is 76 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 76.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.55 | $6.55 |
|---|---|---|
| From the 52-week high | it is 40.3% below its 52-week high (its highest price of the past year) | -40.3% |
| Above the 52-week low | it is 49.8% above its 52-week low (its lowest price of the past year) | +49.8% |
| Below the 52-week high | it is 40.3% below its highest point of the past year | 40.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $38.74 (set on 2021-02-22) | $38.74 |
| Given back of the 52-week move | over the past year its closes ranged ($2.68 to $5.92), and it has recovered roughly a third of its fall from last year’s high — 38% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.68 to $4.79. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 38.0% |
| From the all-time high | it is 89.9% below its all-time high | -89.9% |
| Nearest price level | it is trading 3.9% above a support level at $3.76 — a price it turned at three times since 2024-10-11, most recently on 2026-05-11. Since 2024-08-21 it has 8 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.9% |
| All-time low | its lowest closing price on record is $1.26 (set on 2025-04-04) | $1.26 |
| Above the all-time low | it is 210.3% above its all-time low | +210.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 51st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2511 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2511 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.01 and $4.05 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.01 – $3.53 – $4.05 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 0.6 daily ranges above its 200-day average price (4.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.14× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.7% since the prior reading | -1.7% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 2 sessions ago and has not traded back through the level it left behind at 3.63 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 2.4% gap up opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 21.4 percentage points (the stock gained 23.7% while the market gained 2.3%) | +21.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 21.0 percentage points (the stock gained 24.1% while the market gained 3.1%) | +21.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 13.6 percentage points (the stock lost 2.5% while the market gained 11.1%) | -13.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 11.9 percentage points (the stock gained 8.6% while the market gained 20.5%) | -11.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.2% of the share price. | +10.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.51 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +11.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $3.79 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +3.3% |
Price levels it has turned at before
SANA last closed at $3.91 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.76 | Support | 3.9% below the last close | turned there three times · 2024-10-11 to 2026-05-11 |
| $4.11 | Resistance | 5.0% above the last close | turned there twice · 2024-09-13 to 2026-04-14 |
| $3.69 | Support | 5.6% below the last close | turned there twice · 2024-09-25 to 2026-02-17 |
| $4.37 | Resistance | 11.7% above the last close | turned there three times · 2024-10-16 to 2026-01-20 |
| $3.44 | Support | 12.0% below the last close | turned there twice · 2025-09-11 to 2026-07-27 |
| $4.45 | Resistance | 13.7% above the last close | turned there twice · 2024-10-07 to 2026-02-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $3.03.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $4.63 and $5.62 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $3.03.
This labelling was already in place when we began recording count changes on 2026-08-12, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · Analyst price target recently CUT | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.44 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$8.43 range $6.00 – $12.00; median $7.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SANA
- Consensus EPS estimate-$0.1205 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical and regulatory development timelines are uncertain; SC451 and SG293 are early-stage candidates requiring successful IND filings and Phase 1 trials with no guarantee of safety or efficacy data as planned","Manufacturing and scale-up of cell therapies presents significant technical and operational challenges; ability to produce SC451 and other candidates at commercial scale remains unproven","Substantial ongoing capital requirements with limited revenue; company's future depends on successful development, regulatory approval, and commercialization of product candidates, with no assurance of profitability or sustained funding"]
What changed in the latest 10-Q
AI-assisted comparison of SANA's 10-Q filed 2026-05-11 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 Annual Report filed March 3, 2026 (older filing references 2024 Annual Report filed March 17, 2025)
- Newer filing states therapeutic areas include 'oncology' alongside type 1 diabetes and B-cell mediated autoimmune diseases
- Newer filing introduces SG227 as a CD8-targeted fusosome for BCMA-directed CAR T cells in multiple myeloma, with clinical testing expected mid-2027
- Newer filing states SC451 IND filing and Phase 1 trial expected 'as early as this year' (2026)
- Newer filing states SG293 initial clinical data expected 'as early as this year' (2026)
- Newer filing reports positive 14-month results from UP421 IST announced in March 2026, including no drug product-related adverse events and graft survival through 14 months
- Newer filing confirms 14-month C-peptide production and appropriate islet cell function demonstrated by mixed meal tolerance test
- Newer filing states suspension of SC291 and SC262 development is already in effect and winding down of GLEAM and VIVID trials is ongoing
- Removed:
- Older filing reference to 'repair and control genes' changed to 'repair or control genes' in newer
- Older filing's statement that company is 'preclinically developing SC451' removed; newer filing treats SC451 as an advanced program
- Older filing's reference to UP421 as 'Phase 1 investigator-sponsored first-in-human study' removed; newer simply calls it IST
- Older filing's statement about expecting to file IND and begin Phase 1 for SC451 'as early as 2026' removed (now expected 'as early as this year' in 2026 filing)
- Older filing's six-month UP421 results details (C-peptide presence, mixed meal tolerance test responses, 12-week PET-MRI scanning, 85th ADA Scientific Sessions presentation) partially replaced with 14-month results in newer
- Older filing's reference to SG299 product candidate and comparison data removed; newer filing only references SG293
- Older filing's statement that SG293 IND filing expected 'as early as 2027' removed; newer filing expects clinical data 'as early as this year'
- Older filing's statement about 'beginning to wind down' GLEAM and VIVID trials removed; newer states winding down is occurring
- Reworded:
- Older: 'developing ex vivo and in vivo cell engineering platforms to revolutionize treatment of various diseases' changed to Newer: 'platforms to revolutionize treatment across a broad array of therapeutic areas'
- Older: 'cell-specific delivery of genetic payloads that integrate into the genome' changed to Newer: 'cell-specific delivery of genetic payloads, known as chimeric antigen receptors (CARs)'
- Older: 'allows for cell-specific, in vivo delivery' changed to Newer: 'enables cell-specific, in vivo delivery'
- Older: 'intend to explore SG293 in both B-cell cancers' changed to Newer: 'plan to develop SG293 in a range of B cell cancers'
- Older: 'avoiding potentially troublesome delivery' changed to Newer: 'avoiding potentially problematic delivery'
- Older: 'plan to prioritize further development' and 'have suspended development' changed to Newer: 'prioritization of further development' and 'suspended development' (different verb tenses and structures)
- Notes:
- Newer filing text appears truncated at end ('In August 2025, The New England Journal of Medicine published a journal article titled "Survival of Transplanted Allogeneic Beta Cells'); comparison limited to available text
- Older filing text also appears truncated ('We continue preclinical development of SC451, and recent regulatory interactions, includin'); full sentence unavailable for comparison
Risk Factors
- Added:
- Added to manufacturing expectations in newer filing (2026-05-11): 'and the timing thereof' regarding manufacturing capabilities timing
- Removed:
- Removed from newer filing (2026-05-11): bullet point on 'the potential effects of public health crises on our preclinical and clinical programs and business'
- Removed from newer filing (2026-05-11): bullet point on 'our expectations regarding the impact of global events, geo-political developments, and macroeconomic conditions on our business'
- Notes:
- The provided sections include table of contents and forward-looking statements rather than the full Risk Factors section; comparison is limited to available text
- Page number changes observed (Risk Factors moved from page 37 in older filing to page 35 in newer filing) but this reflects document pagination rather than substantive content change
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SANA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SANA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 64,429,535
- Reported value $185,557,062
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SANA had 42,148,007 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SANA had 14.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 16.33 days to cover at the same settlement.
- Reported short interest (shares) 42,148,007
- Short interest (% of shares outstanding) 14.1%
- Prior settlement (shares) 39,736,380
- Reported change 6.07%
- Days to cover (reported) 16.33
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Vertex Pharmaceuticals (VRTX)
- CRISPR Therapeutics (CRSP)
- Editas Medicine (EDIT)
- Intellia Therapeutics (NTLA)
- Bluebird Bio (BLUE)
- Fate Therapeutics (FATE)
- Novartis (NVS)
- Gilead Sciences (GILD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SANA vs…
SANA BIOTECHNOLOGY INC is found in…
Frequently asked questions
What does SANA BIOTECHNOLOGY INC (SANA) do?
Sana Biotechnology is a clinical-stage cell engineering company developing transformative therapeutics through ex vivo and in vivo cell engineering platforms. The company's lead program, SC451, is a hypoimmune platform (HIP)-engineered stem cell-derived pancreatic islet cell therapy for type 1 diabetes designed to achieve normal blood glucose without insulin injections or immunosuppression.
What sector is SANA BIOTECHNOLOGY INC (SANA) in?
SANA BIOTECHNOLOGY INC (SANA) is classified in the Health Care sector. Its industry is Cell therapy and engineered cell therapeutics. It trades on NASDAQ.
Who are SANA BIOTECHNOLOGY INC's (SANA) competitors?
Notable peers of SANA BIOTECHNOLOGY INC (SANA) include Vertex Pharmaceuticals, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics and Bluebird Bio. This peer set is informational only — not financial advice.
Is SANA BIOTECHNOLOGY INC (SANA) overbought or oversold right now?
SANA BIOTECHNOLOGY INC (SANA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SANA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.